title: Solitary erythema migrans: a clinical, laboratory and epidemiological study of 77 Dutch patients.
abstract: Regional variations in the clinical spectrum of Lyme borreliosis have been described previously. These may be related to strain variations, or reflect selection bias. We compared the clinical and epidemiological profiles of Dutch patients presenting with solitary erythema migrans alone, with the profiles in other European studies, and studies from the U.S.A., and cultured Borrelia burgdorferi from erythema migrans to identify the genospecies. Seventy-seven consecutive patients with a final diagnosis of erythema migrans were admitted into the study. Various clinical and epidemiological data were obtained, and serum was evaluated for antibodies to Borrelia burgdorferi with an enzyme-linked immunosorbent assay. Skin biopsy specimens were taken from the border of the erythema migrans and cultured in modified Kelly's medium. The different genospecies of Borrelia burgdorferi were identified by reactivity with monoclonal antibodies H3TS, LA-26, LA-31 and D6, and by rRNA gene restriction patterns. Patients were treated with tetracycline or doxycycline, and were seen for follow-up 6 weeks after treatment. Long-term follow-up was by telephone interview. A tick bite had been noticed by 45% of the patients. The onset of erythema migrans occurred in 97% of these patients within 3 months of the tick bite. Erythema migrans was present for 1-319 days (median 2 months). No concomitant manifestations were spontaneously reported. Borrelia burgdorferi was cultured from 52 (84%) of 62 skin biopsy specimens. Fifty isolates (96%) were identified as Borrelia burgdorferi group VS461. No therapy failures occurred among patients treated with tetracycline (follow-up 1-4 years, median 27 months) or doxycycline (follow-up 6-31 months, median 19 months).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Neurology, Academisch Medisch Centrum, University of Amsterdam, The Netherlands.
authors.forename: H
authors.initials: H
authors.lastname: Kuiper
authors.forename: I
authors.initials: I
authors.lastname: Cairo
authors.forename: A
authors.initials: A
authors.lastname: Van Dam
authors.forename: B
authors.initials: B
authors.lastname: De Jongh
authors.forename: T
authors.initials: T
authors.lastname: Ramselaar
authors.forename: L
authors.initials: L
authors.lastname: Spanjaard
authors.forename: J
authors.initials: J
authors.lastname: Dankert
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood; D015748:Borrelia burgdorferi Group / Q000276:immunology / Q000302:isolation & purification; D002648:Child; D002675:Child, Preschool; D004318:Doxycycline / Q000627:therapeutic use; D015787:Erythema Chronicum Migrans / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D011446:Prospective Studies; D012867:Skin / Q000382:microbiology; D013752:Tetracycline / Q000627:therapeutic use
chemical_list: D000907:Antibodies, Bacterial; D013752:Tetracycline; D004318:Doxycycline